Table 7.

Comparison of serum CK over time between diagnosis, sex, age, smoking status, and disease duration within a medication group

Parameter	Laboratory marker	Medication	GMR (95% CI)	p value
Diagnosis (CD vs. UC)	CK	Infliximab	0.95 (0.7241; 1.2457)	0.71
		Vedolizumab	1.20 (o.8067; 1.7994)	0.36
Sex (male vs. female)	CK	Infliximab	1.59 (1.2390; 2.0339)	<0.001
		Vedolizumab	1.38 (0.9097; 2.0953)	0.13
Age, years	CK	Infliximab	1.00 (0.9878; 1.0062)	0.52
		Vedolizumab	1.00 (0.9868; 1.0180)	0.77
Smoker (yes vs. no)	CK	Infliximab	0.88 (0.6626; 1.1668)	0.37
		Vedolizumab	1.12 (0.7336; 1.6997)	0.61
Smoker (ex vs. no)	CK	Infliximab	0.66 (0.4699; 0.9291)	0.02
		Vedolizumab	0.82 (0.4409; 1.5116)	0.52
Disease duration	CK	Infliximab	1.00 (0.9879; 1.0134)	0.93
		Vedolizumab	1.00 (0.9728; 1.0202)	0.75

CK, creatine kinase; CI, confidence interval; GMR, geometric mean ratio; CD, Crohn's disease; UC, ulcerative colitis.